According to news from Titan Media App on July 18, data shows that as of July 17, 112 of the 452 biopharmaceutical companies in the A-share market have disclosed their performance forecasts for the first half of 2022. Among them, there are 41 companies whose performance in the first half of the year is expected to increase significantly year-on-year, and 26 companies such as Jiu’an Medical , Kaikai Industrial, and Asymchem are expected to increase their net profit by over 100% year-on-year. The performance of 20 companies, including Kehua Bio, Unnamed Medicine , Harbin Pharmaceutical , and Stellite , is expected to decline sharply year-on-year in the first half of the year. A practitioner in the pharmaceutical industry, who did not want to be named, said that in the biopharmaceutical industry, there is a lot of demand in the fields of in vitro diagnosis, vaccine research and development, and traditional Chinese medicine, so the performance of many companies in the first half of the year has shown positive growth. (Source: Securities Daily)
media coverage
Titanium Media
Related events
- 112 biopharmaceutical companies disclosed the first half of the performance forecast, 26 companies are expected to double the net profit2022-07-17
- Xiaokang shares: pre-loss in the first half of the year 1.6 billion to 1.76 billion 2022-07-14
- Tianqi Lithium: It is estimated that the net profit in the first half of the year is 9.6 billion-11.6 billion yuan, a year-on-year increase of 11089.14%-13420.21% 2022-07-13
- Enjie : It is estimated that the profit in the first half of the year is 1.996 billion yuan to 2.076 billion yuan2022-07-13
- 108 Sci-tech Innovation Board companies predict an increase in their annual results in 20212022-01-28
This article is reprinted from: https://readhub.cn/topic/8hJnRE0Vjtk
This site is for inclusion only, and the copyright belongs to the original author.